CIPLABSECipla LtdMediumNeutral
Announced Wed, 13 May · 13:14 IST

Appointment of Mr Sushrut Kulkarni as Senior Management Personnel of the Company w.e.f 18 May 2026

Management Changes View source PDF

CIPLA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
+10.9%1-day move
₹1293.70
prior close
₹1350.70
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-0.4-0.6-0.5-0.1+10.9+10.4+10.2+8.9+8.2+7.7+8.4+6.8+10.3
Up moveDown movePending
AI summary

Cipla's Board of Directors has approved the appointment of Mr Sushrut Kulkarni as President & Global Chief – Integrated Product Development (IPD), member of the Management Council and Senior Management Personnel of the Company, effective 18th May 2026. Sushrut Kulkarni brings over three decades of pharma experience, having previously served as Global Head – IPDO at Dr Reddy's Laboratories and held senior roles at Glenmark, Zydus Lifesciences, and other companies. He has a strong track record in R&D operations, regulatory filings, and pipeline management across regulated and semi-regulated markets. This appointment is part of Cipla's senior leadership strengthening in its product development function. The Board meeting, held on 13th May 2026, also approved convening the 90th AGM on 25th June 2026, stock option grants to employees, and appointment of cost auditors.

Likely market impact

This is a routine senior management appointment in the R&D/product development space and is unlikely to have any immediate impact on Cipla's stock price. It reflects the company's focus on strengthening its product development capabilities with an experienced pharma professional.